Clinical Trials on Hepatitis C (HCV) in Norway

Total 95 results

Haukeland University Hospital
Hoffmann-La Roche; Bergen Prison, Norwegian Correctional Service

Terminated

Hepatitis C Treatment of Inmates (PEGPRI)

Chronic Hepatitis C

Norway
Ullevaal University Hospital
Schering-Plough

Completed

14 vs 24 Weeks HCV Treatment to Genotype 2/3 Patients With Rapid Virological Response

Hepatitis C Virus Infection

Norway
Haukeland University Hospital
University of Bergen

Unknown

Liver Elastography in Patients Undergoing Treatment for Hepatitis C

Hepatitis C Virus Infection

Norway
AbbVie

Completed

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-I)

Chronic Hepatitis C Virus (HCV) Infection Genotype 1

Algeria, Australia, Belgium, Bulgaria, Canada, Denmark, Finland, France, Germany, Greece, Israel, Italy, Mexico, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Saudi Arabia, Spain, Switzerland, Turkey, Austria, Ireland and more
Haukeland University Hospital
University of Bergen; Helse Stavanger HF; Helse Vest; Forskningsrådet; Folkehelse... and other collaborators

Active, not recruiting

Integrated Treatment of Hepatitis C Virus Infection (INTRO-HCV)

Hepatitis C, Chronic | Opioid Dependence, on Agonist Therapy

Norway
Kirby Institute
Merck Sharp & Dohme LLC

Completed

A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3 (ACTIVATE)

Hepatitis C, Chronic

Australia, Canada, United Kingdom, Belgium, Germany, Norway, Switzerland
Sorlandet Hospital HF

Completed

HEPMET-1: Evaluate the Feasibility, Mental Sideeffects and the Efficacy of Hepatitis C Treatment in a MMT Group.

Hepatitis | Opiate Dependence

Norway
University Hospital, Akershus

Completed

Opportunstic Hepatitis C Virus Treatment (Opportuni-C)

Hepatitis C | Substance Use Disorders

Norway
University Hospital, Akershus

Unknown

HCV Treatment in a Low-threshold Clinic (Prindsen)

Hepatitis C | Substance Use Disorders

Norway
Kirby Institute

Recruiting

Australian Hepatitis and Risk Survey in Prisons (AusHep)

HIV Infections | Hepatitis B | Hepatitis C

Australia
Boehringer Ingelheim

Completed

IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1

Hepatitis C, Chronic

United States, Austria, Canada, France, Germany, Hungary, Ireland, Italy, Netherlands, Portugal, Romania, Russian Federation, Spain, United Kingdom
Kirby Institute
National Health and Medical Research Council, Australia

Recruiting

ETHOS ENGAGE: Enhancing Treatment of Hepatitis C in Opioid Substitution Settings (ETHOS II)

Hepatitis C

Australia
Tibotec Pharmaceuticals, Ireland

Completed

A Study of TMC435 in Combination With Pegylated Interferon Alp\Fa-2a and Ribavirin in Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received Treatment (PILLAR)

Hepatitis C

United States, Australia, France, Belgium, Germany, Spain, Denmark, Canada, New Zealand, Russian Federation, Austria, Poland, Norway
Tibotec Pharmaceuticals, Ireland

Completed

A Safety and Effectiveness Study of TMC435 in Chronic, Genotype 1, Hepatitis C Patients Who Failed to Previous Standard Treatment (ASPIRE)

Hepatitis C

United States, Australia, France, United Kingdom, Belgium, Germany, Israel, Portugal, Canada, New Zealand, Russian Federation, Austria, Poland, Norway
Boehringer Ingelheim

Completed

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2)

Hepatitis C

United States, Canada, Korea, Republic of, Puerto Rico, Taiwan
Janssen R&D Ireland

Completed

TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy (ATTAIN)

Hepatitis C

United States, Australia, France, Poland, United Kingdom, Germany, Spain, Belgium, Israel, Portugal, Bulgaria, Romania, Denmark, Greece, Sweden, Canada, Czech Republic, Argentina, Brazil, Austria, Hungary, Switzerland, Puerto Rico, No...
Sorlandet Hospital HF

Recruiting

Non-invasive Diagnostics of Microbial Keratitis

Infectious Keratitis

Norway
Diakonhjemmet Hospital
University Hospital, Akershus

Active, not recruiting

Vaccine Response to COVID-19 Vaccines in Patients Using Immunosuppressive Medication (Nor-vaC)

Rheumatoid Arthritis | Crohn Disease | Ulcerative Colitis | Autoimmune Hepatitis | Psoriatic Arthritis | Liver Transplant; Complications | Spondyloarthritis

Norway
Oslo University Hospital
Karolinska University Hospital; Hvidovre University Hospital; Addis Ababa University and other collaborators

Completed

The Norwegian Nucleoside Analogue Stop Study (Nuc-Stop)

Hepatitis B, Chronic

Norway, Denmark, Ethiopia, Sweden
Helse Stavanger HF
Tor Paaske Utheim; Vegard Asgeir Forsaa; Vilde Marie Thomseth

Enrolling by invitation

Epidemiological Study of Dry Eye Disease in Stavanger: Dry Eye Disease in Patients Treated With Intravitreal Injections (EPISTA1)

Dry Eye

Norway
Dag Kvale
The Research Council of Norway

Completed

Immunomodulating Therapy and Improved Vaccination Responses by Cox-2 Inhibitor in HIV-infected Patients (OUSCOX2)

HIV

Norway
Oslo University Hospital
Schepens Eye Research Institute; The Norwegian Dry Eye Clinic

Completed

Optimization of the Treatment of Dry Eye Disease Caused by Meibomian Gland Dysfunction

Dry Eye Syndromes | Meibomian Gland Dysfunction

Norway
The Norwegian Dry Eye Clinic
Laboratoires Thea

Recruiting

Comparison of Two Types of Artificial Tears

Dry Eye Disease

Norway
Bionor Immuno AS

Completed

Immunotherapy With Vacc-C5 With Adjuvant GM-CSF or Alhydrogel in HIV-1-infected Subjects on ART

HIV-1 Infection

Norway
GlaxoSmithKline

Completed

Study to Evaluate Antibody Persistence in Children Previously Vaccinated With Infanrix Hexa™ or Infanrix-IPV/Hib™

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b | Diphtheria-Tetanus-aPertussis-Poliomyelitis-Haemophilus Influenzae Type b Vaccines

Sweden, Norway
Ifocus Oyeklinikk
The Research Council of Norway

Recruiting

Metabolomic Profile in Dry Eye Syndrome Patients.

Cataract | Dry Eye Syndromes

Norway
Oslo University Hospital
Eurocine Vaccines AB; Bionor Immuno AS

Completed

Intranasal Modified Vacc-4x Gag Peptides With Endocine as Adjuvant

HIV Infection

Norway
Rigshospitalet, Denmark
University College, London

Enrolling by invitation

EuroSIDA - Clinical and Virological Outcome of European Patients Infected With HIV (EuroSIDA)

End Stage Liver Disease | Cardiovascular Diseases | Fractures, Bone | Diabetes Mellitus | Renal Insufficiency | Hepatitis B | Hepatitis C | Kidney Failure, Chronic | Proteinuria | HIV | Coinfection | Acidosis, Lactic | AIDS

Spain, Switzerland, Germany, United Kingdom, Austria, Sweden, Finland, Israel, Denmark, France, Italy, Iceland, Belgium, Slovakia, Norway, Lithuania, Portugal, Poland, Croatia, Czechia, Greece, Hungary, Luxembourg, Argentina, Belarus, Bosnia... and more
Oslo University Hospital
Karolinska University Hospital; Tine

Completed

The Effect of Probiotics in HIV-1 Infection (ProGut)

HIV-1 Infection

Norway, Sweden
Eiger BioPharmaceuticals

Completed

Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a (D-LIVR)

Hepatitis Delta Virus

United States, Belgium, Spain, Greece, Canada, Italy, Romania, Germany, Israel, Bulgaria, Taiwan, Turkey, Pakistan, Sweden, Ukraine, New Zealand, Russian Federation, United Kingdom, Moldova, Republic of, France, Mongolia, Switzerland
Oslo University Hospital
University of Oslo

Completed

Improving Prognosis in HIV Infection

Human Immunodeficiency Virus

Norway
Makerere University
The Norwegian Programme for Development, Research and Higher Education

Completed

Effect of Multiple Micronutrient Supplementation on Growth, Morbidity, and Mortality of HIV Infected Children in Uganda (MMS)

HIV Infections

Norway, Uganda
Oslo University Hospital
University of Oslo; Ullevaal University Hospital; University Hospital, Akershus

Withdrawn

Postnatal HCMV Infection in Very Preterm Infants. Implications, Morbidity, Growth and Neurodevelopmental Outcomes.

Microcephaly | Hearing Loss | Mental Retardation | Chorioretinitis

Norway
Oslo University Hospital

Unknown

Evaluation of Implementation of Pre-exposure Prophylaxis (PrEP) in Norway

Sexually Transmitted Diseases | Hiv | Mental Health Wellness 1

Norway
University of Aarhus
Odense University Hospital; Oslo University Hospital; Rigshospitalet, Denmark; Hvidovre... and other collaborators

Completed

Combining TLR9 Agonist With bNAbs for Reservoir Reduction and Immunological Control of HIV (TITAN)

HIV-1-infection

Norway, Denmark, United States, Australia
AstraZeneca

Terminated

JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events

Elevated High-sensitivity C-Reactive Protein (hsCRP)

United States, Brazil, Bulgaria, Poland, Russian Federation, South Africa, United Kingdom, Germany, Estonia, Romania, Denmark, Netherlands, Norway, Canada, Mexico, Belgium, Israel, Puerto Rico, Colombia, Argentina, Venezuela, Panama, Urugu... and more
Exact Sciences Corporation

Recruiting

ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk

Hepatitis B | Hepatocellular Carcinoma | Cirrhosis | Liver Cancer | Hepatocellular Cancer

United States
City of Hope Medical Center
Sangamo Therapeutics; California Institute for Regenerative Medicine (CIRM)

Active, not recruiting

Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients

HIV

United States
Sangamo Therapeutics

Terminated

Long-term Follow-up of HIV Subjects Exposed to SB-728-T or SB-728mR-T

HIV-1-infection

United States
AIM ImmunoTech Inc.

Terminated

Safety and Efficacy of Ampligen in the Treatment of HIV Patients Failing HAART

HIV Infection | HIV Seropositivity

United States
Sangamo Therapeutics

Completed

Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART

Human Immunodeficiency Virus (HIV)

United States
VIRxSYS Corporation

Active, not recruiting

A Rollover Study for Subjects Who Completed Participation in the VRX496-USA-05-002 Trial (Rollover)

HIV Infections

United States
VIRxSYS Corporation

Active, not recruiting

Safety and Efficacy of T Cell Genetic Immunotherapy for HIV

HIV Infection

United States
AIM ImmunoTech Inc.

Completed

The Role of Ampligen in Strategic Therapeutic Intervention (STI) of HAART

HIV Infection | HIV Seropositivity

United States
Nykode Therapeutics ASA
Merck Sharp & Dohme LLC

Recruiting

Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma

HNSCC | HPV-Related Squamous Cell Carcinoma

France, Norway, Spain, United Kingdom, Hungary, Poland, Czechia, Germany
Sangamo Therapeutics

Completed

Dose Escalation Study of Cyclophosphamide in HIV-Infected Subjects on HAART Receiving SB-728-T

HIV

Puerto Rico, United States
CytoDyn, Inc.

Active, not recruiting

Study of PRO 140 SC as Single Agent Maintenance Therapy in Virally Suppressed Subjects With CCR5-tropic HIV-1 Infection

HIV

United States
Pfizer

Terminated

A Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation (REALM-DCM)

Dilated Cardiomyopathy | Lamin A/C Gene Mutation

United States, Spain, Canada, Belgium, Italy, Argentina, Mexico, Netherlands, Norway, United Kingdom
TaiMed Biologics Inc.

Completed

Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV

HIV

United States, Taiwan, Puerto Rico
GlaxoSmithKline

Terminated

Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5/X4-Tropic Treatment-Experienced HIV-Infected Subjects

HIV Infection

United States, Belgium

Clinical Trials on Hepatitis C (HCV) in Norway

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Türkiye

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations